In the last few years, an increasing number of small-molecule anti-cancer drugs, the so-called GTPase inhibitors as well as others, has been tested in clinical trials, generating encouraging results with improved efficacy of lung cancer treatment for KRAS-mutated NSCLC. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.